nach oben

Cancer Chemotherapy and Pharmacology

Erschienen in:

01.11.2007 | Original Article

Sonodynamic therapy on chemically induced mammary tumor: pharmacokinetics, tissue distribution and sonodynamically induced antitumor effect of gallium–porphyrin complex ATX-70

verfasst von: Nagahiko Yumita, Nobuo Okuyama, Kazuaki Sasaki, Shin-ichiro Umemura

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 6/2007

Einloggen, um Zugang zu erhalten

Abstract

Sonodynamically induced antitumor effect of a gallium porphyrin complex, ATX-70 was evaluated on a chemically induced mammary tumor in Sprague–Dawley rats. The timing of 24 h after the administration of ATX-70 was chosen for ultrasonic exposure, based on pharmacokinetic analysis of ATX-70 concentrations in the tumor, plasma, skin, and muscle. At an ATX-70 dose not less than 2.5 mg/kg and at a free-field ultrasonic intensity not less than 3 W/cm², the synergistic effect between ATX-70 administration and ultrasonic exposure on the tumor growth inhibition was significant. These results suggest that ATX-70 is a potential sonosensitizer for sonodynamic treatment of spontaneous mammary tumors.

Abe H, Kuroki K, Tachibana K, Awasthi A, Ueno A, Matsumoto H, Imakiire T, Yamauchi Y, Yamada H, Ariyoshi A, Kuroki M (2002) Targeted sonodynamic therapy of cancer using a photosensitizer conjugated with antibody against carcinoembryonic antigen. Anticancer Res 22:1575–1580PubMed

Agarwal R, Athar M, Elmets CA, Bickers DR, Mukhtar H (1990) Photodynamic therapy of chemically- and ultraviolet B radiation-induced murine skin papillomas by chloroaluminum phthalocyanine tetrasulfonate. Photochem Photobiol 56:43–50

Bellnier DA, Ho YK, Panday RK, Missert JR, Dougherty TJ (1989) Distribution and elimination of Photofrin II in mice. Photochem Photobiol 50:221–228PubMedCrossRef

Brueggemeier RW, Li PK (1990) Effects of the aromatase inhibitor 7 alpha- (4′-amino) phenylthio-4-androstene-3, 17-dione on 7,12-dimethylbenz (a) anthracene-induced mammary carcinoma in rats. Cancer Res 48:6808–6810

Dougherty TJ (1993) Photodynamic therapy. Photochem Photobiol 58:895–905PubMed

Jin ZH, Miyoshi N, Ishiguro K, Umemura S, Kawabata K, Yumita N, Sakata I, Takaoka K, Udagawa T, Nakajima S, Tajiri H, Ueda K, Fukuda M, Kumakiri M (2000) Combination effect of photodynamic and sonodynamic therapy on experimental skin squamous cell carcinoma in C3H/HeN mice. J Dermatol 27:294–306PubMed

Kessel D (1986) Porphyrin-lipoprotein association as a factor in porphyrin loacatization. Cancer Lett 33:183–188PubMedCrossRef

Nakajima S, Maeda T, Omote Y, Hayashi H, Yamazaki K, Kobo Y, Takemura S, Shindo Y, Sakata I (1989) Tumor localizing Ga–porphyrin complex (ATX-70) as a new photosensitizer excited with YAG-laser. J Jpn Soc Laser Med 10:225–228

Okuyama N, Sasamoto S, Kato N, Takagi K, Yamazaki S, Tsujimoto S, Yumita N, Nishigaki R, K.Sasaki, Umemura S (2000) The effect of sonodynamic therapy on rat mammary cancer (in Japanese). J Med Ultrasonics 27:1465–1469

10.

Roy RA, Atchley AA, Crum LA, Fowlkes JB, Reidy JJ (1985) A precise technique for the measurement of acoustic cavitation thresholds and some preliminary results. J Acoust Soc Am 78:1799–1805PubMedCrossRef

11.

Umemura S, Yumita N, Nishigaki R, Umemura K (1990) Mechanism of cell damage by ultrasound in combination with hematoporphyrin. Jpn J Cancer Res 81:962–966PubMed

12.

Umemura K, Yumita N, Nishigaki R, Umemura S (1996) Sonodynamically induced antitumor effect of pheophorbide a. Cancer Lett 102:151–157PubMedCrossRef

13.

Umemura S, Yumita N, Nishigaki R (1993) Enhancement of ultrasonically induced cell damage by a gallium–porphyrin complex, ATX-70. Jpn J Cancer Res 84:582–588PubMed

14.

Umemura S, Sasaki K, Kawabata K (1995) Reduction of threshold for producing sonodynamic tissue damage by second-harmonic superimposition. In: Proceedings of 1995 IEEE ultrasonics symposium, pp 1567–1570

15.

Yumita N, Nishigaki R, Umemura K, Umemura S (1989) Hematoporphyrin as a sensitizer of cell damaging effect of ultrasound. Jpn J Cancer Res 80:219–222PubMed

16.

Yumita N, Nishigaki R, Umemura K, Umemura S (1990) Synergetic effect of ultrasound and hematoporphyrin on sarcoma 180. Jpn J Cancer Res 81:304–308PubMed

17.

Yumita N, Sasaki K, Umemura S, Nishigaki R (1996) Sonodynamically induced antitumor effect of a gallium–porphyrin complex, ATX-70. Jpn J Cancer Res 87:310–316PubMed

18.

Yumita N, Umemura S (2000) Sonodynamic therapy with photofrin II on AH130 solid tumor. Pharmacokinetics, tissue distribution and sonodynamic antitumoral efficacy of photofrin II. Cancer Chemother Pharmacol 51:74–78

19.

Yumita N, Nishigaki R, Sakata I, Nakajima S, Umemura S (2000) Sonodynamically induced antitumor effect of 4-formyloximethylidene-3-hydroxy-2-vinyl-deuterio-porphynyl(IX)-6,7-diaspartic acid (ATX-S10). Jpn J Cancer Res 91:255–260PubMed

20.

Yumita N, Okuyama N, Sasaki K, Umemura S (2004) Sonodynamic therapy on chemically induced mammary tumor: pharmacokinetics, tissue distribution and sonodynamically induced antitumor effect of porfimer sodium. Cancer Sci 95:765–769PubMedCrossRef

Titel: Sonodynamic therapy on chemically induced mammary tumor: pharmacokinetics, tissue distribution and sonodynamically induced antitumor effect of gallium–porphyrin complex ATX-70
verfasst von: Nagahiko Yumita
Nobuo Okuyama
Kazuaki Sasaki
Shin-ichiro Umemura
Publikationsdatum: 01.11.2007
Verlag: Springer-Verlag
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 6/2007
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-007-0436-5

Neu im Fachgebiet Onkologie

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Brustkrebs-Prävention wird neu gedacht

04.06.2024 ASCO 2024 Kongressbericht

Zurzeit untersuchen Forschende verschiedene neue Ansätze zur Prävention von Brustkrebs bei Personen mit hohem Risiko. Darunter Denosumab, die prophylaktische Bestrahlung der Brust – und Impfungen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2007

Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer

Validation of the comet-X assay as a pharmacodynamic assay for measuring DNA cross-linking produced by the novel anticancer agent RH1 during a phase I clinical trial

Tissue distribution and depletion kinetics of bortezomib and bortezomib-related radioactivity in male rats after single and repeated intravenous injection of 14C-bortezomib

O 4-benzylfolic acid inactivates O 6-alkylguanine-DNA alkyltransferase in brain tumor cell lines

A pharmacokinetic study on Z-(±)-2-(1-benzylindole-3-yl-methylene)azabicyclo[2.2.2]octane-3-ol; a novel radio-sensitization agent